Introducing the Adcendo
leadership team
Michael Pehl, MSc
CEO
+25 years of global pharmaceutical & biotech leadership experience. Former CEO of GEMoaB, CEO of Immunomedics, and President of Hematology & Oncology at Celgene
Dominik Mumberg, PhD
CSO
25 years of experience in therapeutic
innovation, translational sciences, pre-clinical and clinical development in oncology at Bayer. Most recently Translational Innovation Lead, with a focus on ADCs, radiotherapies, targeted therapies, small molecules and target identification
Carmel M. Lynch, PhD
CDO
+25 years of experience in biotechnology, spanning from discovery research to clinical development, with an emphasis in translational medicine. +15 years specializing in ADCs; led Nonclinical and Clinical Pharmacology development of Adcetris(tm) ADC at SeaGen from pre-IND to approval in 2011
Pernille Hemmingsen, PhD
CTO
+20 years experience in the pharmaceutical industry. Former VP, Global Product Development and Supply at Savara ApS. 5 years at Genmab, leading ADC CMC and manufacturing, from non-clinical to phase II development
Christoffer Nilelsen, PhD
COO & Co-Founder
Established the scientific project on utilization of receptors for targeted drug delivery by ADCs at The Finsen Laboratory, which became Adcendo. Molecular Biologist by training, founding CTO of Adcendo from 2017-2021
James Wang
Head of Business Development
10+ years of consulting and global biopharmaceutical experience across strategy and business development. Former Senior Director BD at Innovent, Head of Search & Evaluate Immunology at Simcere and Associate Director Global Product & Portfolio Strategy at AstraZeneca
Lasse René Sørensen
Finance Director
Lasse René Sørensen has experience from 11 years at Deloitte in the consulting practice with primarily focus on Accounting & Reporting advisory and Disruptive events, such as M&A activities and IPO journeys
Karen Bannister
Executive Director Program Management
+25 years of experience in the biotech and pharmaceutical industry across development lifecycle most recently as CMC project lead to approval of Adtralza® at Leo Pharma